Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 874Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Hematologic Neoplasms 462Leukemia, Lymphocytic, Chronic, B-Cell 388Leukemia 328Myelodysplastic Syndromes 324Lymphoma 203Lymphoma, Non-Hodgkin 191Multiple Myeloma 145Leukemia, Myelogenous, Chronic, BCR-ABL Positive 139Recurrence 136Neoplasms 133Leukemia, Myelomonocytic, Chronic 110Burkitt Lymphoma 92Lymphoma, Mantle-Cell 91Lymphoma, Follicular 91Lymphoma, Large B-Cell, Diffuse 88Myeloproliferative Disorders 84Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Leukemia, Biphenotypic, Acute 79Lymphoma, B-Cell, Marginal Zone 75Hodgkin Disease 72Lymphoma, B-Cell 64Waldenstrom Macroglobulinemia 54Primary Myelofibrosis 53Leukemia, B-Cell 50Anemia, Refractory, with Excess of Blasts 45Leukemia, Myeloid, Chronic-Phase 40Hematologic Diseases 37Lymphoma, T-Cell 32

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Other hematologic neoplasm × 1 year × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡